Secukinumab treatment and vaccination efficacy.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical and experimental dermatology"
DOI: 10.1111/ced.15004
Abstract: Dear Editor, Secukinumab, a monoclonal antibody against interleukin (IL)-17A, is used to treat psoriasis and psoriatic arthritis. The effect of this treatment on COVID-19 vaccination is not well characterized. While IL-17 deficiency states are associated… read more here.
Keywords: dermatology; vaccination efficacy; treatment; secukinumab treatment ... See more keywords